Modifying cardiovascular risk factors: Newer insights and preventive measures

Current Pharmaceutical Design

Volumn 15, Issue 10, 2009, Pages 1034-1037

  Landini, Luigi ^a   Mikhailidis, Dimitri P ^b   Leone, Aurelio ^c  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CONTRAST MEDIUM; FLAVANOL DERIVATIVE; FLAVONOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITOCHONDRIAL DNA; POLYPHENOL DERIVATIVE; PROTEINASE; REACTIVE OXYGEN METABOLITE; THROMBOXANE A2;

ATHEROSCLEROSIS; AUTOPHAGY; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CIGARETTE SMOKING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DIET THERAPY; DISEASE COURSE; DYSLIPIDEMIA; EDITORIAL; ENDOTHELIUM CELL; HEALTH CARE COST; HEART FAILURE; HEART MUSCLE CELL; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LIPID METABOLISM; LYSOSOME; MITOCHONDRION; MORBIDITY; MORTALITY; OBESITY; OXIDATIVE STRESS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREVALENCE; PREVENTIVE MEDICINE; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY; STEM CELL; STENT; THROMBOEMBOLISM;

CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS;

EID: 65649124146     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787846955     Document Type: Editorial

References (25)

1. Armani C, Landini L Jr, Leone A. Molecular and biochemical changes of the cardiovascular system due to smoking exposure. Curr Pharm Des 2009; 15(10): 1038-53.
2. Tziomalos K, Kakafika AI, Athyros VG, Karagiannis A, Mikhailidis DP. The role of statins for the primary and secondary prevention of coronary heart disease in women. Curr Pharm Des 2009; 15(10): 1054-62.
3. Virdis A, Ghiadoni L, Masi S, Versari D, Daghini E, Giannarelli C, et al. Obesità in the childhood. A link to adult hypertension. Curr Pharm Des 2009; 15(10): 1063-71.
4. Grassi D, Desideri G, Croce G, Tiberti S, Aggio A, Ferri C.Flavonoids, vascular function and cardiovascular protection. Curr Pharm Des 2009; 15(10): 1072-84.
5. Papathanasiou A, Goudevenos J, Tselepis AD. Aspirin resistance in cardiovascular disease: pathogenesis, diagnosis and clinical impact. Curr Pharm Des 2009; 15(10): 1085-94.
6. Di Stefano R, Felice F, Balbarini A. Angiogenesis as risk factor for plaque vulnerability. Curr Pharm Des 2009; 15(10): 1095-106.
7. Barsotti MC, Di Stefano R, Spontoni P, Chimenti D, Balbarini A. Role of endothelial progenitor cell mobilization after percutaneous angioplasty procedure. Curr Pharm Des 2009; 15(10): 1107-22.
8. Landini L, Ripoli A, Santarelli MF, Landini L Jr., Positano V. The biological effects of diagnostic cardiac imaging. Curr Pharm Des 2009; 15(10): 1123-30.
9. Andreassi MG, Gastaldelli A, Clerico A, Salvatori P, Sicari R, Picano E. Imaging and laboratory biomarkers in cardiovascular disease. Curr Pharm Des 2009; 15(10): 1131-41.
10. Lazzini A, Lazzini S. Cardiovascular disease: an economical perspective. Curr Pharm Des 2009; 15(10): 1142-56.
11. GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial) a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231-39.
12. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JGF, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-61.
13. Daskalopoulou SS, Delaney JA, Filion KB, Brophy JM, Mayo NE, Suissa S. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J 2008; Epub ahead of print.
14. Liberopoulos EN, Florentin M, Mikhailidis DP, Elisaf MS. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf 2008; 7(6): 717-25.
15. Tziomalos K, Athyros VG, Mikhailidis DP. Statin discontinuation: an underestimated risk? Curr Med Res Opin 2008. Epub ahead of print.
16. Werner N, Junk S, Laufs U, Link A, Walenta B, Bohm M, Nickering G. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res 2003; 93: E 17-24.
17. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
18. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM Jr., Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
19. Mann JM, Davies MJ. Vulnerable plaque: Relation of characteristics to degree of stenosis in human coronary arteries. Circulation 1996; 94: 928-31.
20. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease. 10,158 incident cases among 262,525 partecipants in 29 Western Prospective Study. Circulation 2007; 115: 450-8.
21. Leone A, Landini L Jr., Biadi O, Balbarini A. Smoking and cardiovascular system: cellular features of the damage. Curr Pharm Des 2008; 14: 1771-77.
22. Stephens JW, Humphries SE. The molecular genetics of cardiovascular disease: clinical implications. J Inter Med 2003; 253: 120-27.
23. Leone A. Relationship between cigarette smoking and other coronary risk factors in atherosclerosis: Risk of cardiovascular disease and preventive measures. Curr Pharm Des 2003; 9: 2417-23.
24. Iestra JA, Kromhout D, van der Schouw YT, Grobbee DE, Boshuizen HC, van Staveren WA. Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients. A systematic review. Circulation 2005; 112: 924-34.
25. Leone A. Passive smoking exposure and cardiovascular health. In: Jeorgensen NA Ed. Passive Smoking and Health Research, Nova Publishers, Inc.: New York 2007; 65-94.